1. Home
  2. WPP vs RVMD Comparison

WPP vs RVMD Comparison

Compare WPP & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WPP
  • RVMD
  • Stock Information
  • Founded
  • WPP 1985
  • RVMD 2014
  • Country
  • WPP United Kingdom
  • RVMD United States
  • Employees
  • WPP N/A
  • RVMD N/A
  • Industry
  • WPP Advertising
  • RVMD Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • WPP Consumer Discretionary
  • RVMD Health Care
  • Exchange
  • WPP Nasdaq
  • RVMD Nasdaq
  • Market Cap
  • WPP N/A
  • RVMD 8.7B
  • IPO Year
  • WPP N/A
  • RVMD 2020
  • Fundamental
  • Price
  • WPP $37.96
  • RVMD $35.36
  • Analyst Decision
  • WPP Hold
  • RVMD Strong Buy
  • Analyst Count
  • WPP 1
  • RVMD 13
  • Target Price
  • WPP N/A
  • RVMD $67.77
  • AVG Volume (30 Days)
  • WPP 327.0K
  • RVMD 1.3M
  • Earning Date
  • WPP 02-27-2025
  • RVMD 05-07-2025
  • Dividend Yield
  • WPP 3.16%
  • RVMD N/A
  • EPS Growth
  • WPP 389.11
  • RVMD N/A
  • EPS
  • WPP 0.62
  • RVMD N/A
  • Revenue
  • WPP $18,454,623,978.00
  • RVMD N/A
  • Revenue This Year
  • WPP N/A
  • RVMD N/A
  • Revenue Next Year
  • WPP $2.26
  • RVMD $154.60
  • P/E Ratio
  • WPP $12.20
  • RVMD N/A
  • Revenue Growth
  • WPP N/A
  • RVMD N/A
  • 52 Week Low
  • WPP $37.33
  • RVMD $29.55
  • 52 Week High
  • WPP $57.37
  • RVMD $62.40
  • Technical
  • Relative Strength Index (RSI)
  • WPP 26.49
  • RVMD 33.34
  • Support Level
  • WPP $39.45
  • RVMD $37.42
  • Resistance Level
  • WPP $41.01
  • RVMD $39.59
  • Average True Range (ATR)
  • WPP 0.57
  • RVMD 1.34
  • MACD
  • WPP 0.02
  • RVMD -0.14
  • Stochastic Oscillator
  • WPP 16.54
  • RVMD 10.41

About RVMD Revolution Medicines Inc.

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Share on Social Networks: